VCM
FATE icon

Versant Capital Management’s Fate Therapeutics FATE Stock Holding History

Versant Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-83
Closed -$363 – 1970
2024
Q1 		$609 Hold
83
– – ﹤0.01% 1652
2023
Q4 		$310 Buy
+83
New +$196 ﹤0.01% 1780

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Versant Capital Management's FATE Position: Q2 2024 in Review

Versant Capital Management sold out of Fate Therapeutics (FATE) in Q2 2024, closing a stake of 83 shares — an estimated $363 sold.

Versant Capital Management first reported a position in FATE in Q4 2023 and held it in 2 quarters. The position peaked at $609 in Q1 2024. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • Versant Capital Management reported no remaining Fate Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Versant Capital Management sold 83 Fate Therapeutics shares in Q2 2024, an estimated $363.
  • Versant Capital Management first reported a position in Fate Therapeutics in Q4 2023 and held it in 2 quarters.
  • Versant Capital Management's Fate Therapeutics position peaked at $609 in Q1 2024.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on Versant Capital Management's 13F filing for Q2 2024, filed 8 Jul 2024.